12403
2012
eng
379
13
article
1
2016-01-12
--
--
Treatment-independent miRNA signature in blood of wilms tumor patients
Background
Blood-born miRNA signatures have recently been reported for various tumor diseases. Here, we compared the miRNA signature in Wilms tumor patients prior and after preoperative chemotherapy according to SIOP protocol 2001.
Results
We did not find a significant difference between miRNA signature of both groups. However both, Wilms tumor patients prior and after chemotherapy showed a miRNA signature different from healthy controls. The signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after chemotherapy an accuracy of 97.0%, each as compared to healthy controls.
Conclusion
Our results provide evidence for a blood-born Wilms tumor miRNA signature largely independent of four weeks preoperative chemotherapy treatment.
BMC Genomics
10.1186/1471-2164-13-379
urn:nbn:de:bvb:20-opus-124034
BMC Genomics 2012, 13:379. doi:10.1186/1471-2164-13-379
Jana Schmitt
Christina Backes
Nasenien Nourkami-Tutdibi
Petra Leidinger
Stephanie Deutscher
Markus Beier
Manfred Gessler
Norbert Graf
Hans-Peter Lenhof
Andreas Keller
Eckart Meese
eng
uncontrolled
miRNA
Menschliche Anatomie, Zytologie, Histologie
open_access
Theodor-Boveri-Institut für Biowissenschaften
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/12403/Schmitt_10.1186_1471-2164-13-379.pdf
13379
2011
eng
e28951
12
6
article
1
2016-05-20
--
--
Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients
Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.
PLoS ONE
10.1371/journal.pone.0028951
urn:nbn:de:bvb:20-opus-133794
PLoS ONE 6(12): e28951. doi:10.1371/journal.pone.0028951
false
true
Jana Schmitt
Andreas Keller
Nasenien Nourkami-Tutdibi
Sabrina Heisel
Nunja Habel
Petra Leidinger
Nicole Ludwig
Manfred Gessler
Norbert Graf
Frank Berthold
Hans-Peter Lenhof
Eckart Meese
eng
uncontrolled
Heparan-sulfate
eng
uncontrolled
N-Myc
eng
uncontrolled
Serum autoantibodies
eng
uncontrolled
Suppressors EXT1
eng
uncontrolled
Neuro-blastoma
eng
uncontrolled
Allelic loss
eng
uncontrolled
Lung-cancer
eng
uncontrolled
Children
eng
uncontrolled
Amplification
eng
uncontrolled
Therapy
Biowissenschaften; Biologie
open_access
Theodor-Boveri-Institut für Biowissenschaften
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/13379/016_Schmitt_PlosONE.PDF